Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Kissei Pharmaceutical Co ( (JP:4547) ) is now available.
Kissei Pharmaceutical’s board has approved a share buyback of up to 1.3 million common shares, representing 3.14% of its outstanding stock, for a maximum of 6 billion yen. The repurchases will run from May 12 to December 31, 2026, via market purchases on the Tokyo Stock Exchange, including use of the ToSTNeT-3 off-auction system.
All shares acquired under this program will be cancelled promptly after the buyback is completed, effectively reducing the company’s share count. The move is aimed at executing a more flexible capital policy, improving capital efficiency, and enhancing shareholder returns, signaling a shareholder-friendly stance in response to changing business conditions.
The most recent analyst rating on (JP:4547) stock is a Buy with a Yen5400.00 price target. To see the full list of analyst forecasts on Kissei Pharmaceutical Co stock, see the JP:4547 Stock Forecast page.
More about Kissei Pharmaceutical Co
Kissei Pharmaceutical Co., Ltd. is a Japan-based drugmaker listed on the Tokyo Stock Exchange Prime Market, focusing on the research, development, and sale of pharmaceutical products. The company operates in the healthcare and life sciences industry, targeting domestic and global markets with prescription medicines and related therapies.
YTD Price Performance: -4.01%
Average Trading Volume: 88,707
Technical Sentiment Signal: Buy
Current Market Cap: Yen178.5B
See more data about 4547 stock on TipRanks’ Stock Analysis page.